BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19345439)

  • 1. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.
    Zeuzem S; Gane E; Liaw YF; Lim SG; DiBisceglie A; Buti M; Chutaputti A; Rasenack J; Hou J; O'Brien C; Nguyen TT; Jia J; Poynard T; Belanger B; Bao W; Naoumov NV
    J Hepatol; 2009 Jul; 51(1):11-20. PubMed ID: 19345439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
    Liaw YF; Gane E; Leung N; Zeuzem S; Wang Y; Lai CL; Heathcote EJ; Manns M; Bzowej N; Niu J; Han SH; Hwang SG; Cakaloglu Y; Tong MJ; Papatheodoridis G; Chen Y; Brown NA; Albanis E; Galil K; Naoumov NV;
    Gastroenterology; 2009 Feb; 136(2):486-95. PubMed ID: 19027013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.
    Tsai MC; Lee CM; Chiu KW; Hung CH; Tung WC; Chen CH; Tseng PL; Chang KC; Wang JH; Lu SN; Yen YH; Hu TH
    J Antimicrob Chemother; 2012 Mar; 67(3):696-9. PubMed ID: 22174039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telbivudine versus lamivudine in patients with chronic hepatitis B.
    Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
    N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients.
    Cai W; Xie Q; An B; Wang H; Zhou X; Zhao G; Guo Q; Gu R; Bao S
    J Clin Virol; 2010 May; 48(1):22-6. PubMed ID: 20233672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
    Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
    Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different models of HBeAg seroconversion predicated by on-treatment ALT and HBV DNA profiles.
    You H; Ma H; Liu T; Cong M; Wang P; Ou X; Wang X; Ren J; Li H; Wang B; Jia J
    J Viral Hepat; 2009 Dec; 16(12):876-82. PubMed ID: 19635048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.
    Ma SW; Huang X; Li YY; Tang LB; Sun XF; Jiang XT; Zhang YX; Sun J; Liu ZH; Abbott WG; Dong YH; Naoumov NV; Hou JL
    J Hepatol; 2012 Apr; 56(4):775-81. PubMed ID: 22173154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.
    Gane EJ; Wang Y; Liaw YF; Hou J; Thongsawat S; Wan M; Moon YM; Jia J; Chao YC; Niu J; Leung N; Samuel D; Hsu CW; Bao W; Lopez P; Avila C
    Liver Int; 2011 May; 31(5):676-84. PubMed ID: 21457439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection.
    Han GR; Cao MK; Zhao W; Jiang HX; Wang CM; Bai SF; Yue X; Wang GJ; Tang X; Fang ZX
    J Hepatol; 2011 Dec; 55(6):1215-21. PubMed ID: 21703206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients.
    Lü W; Yang HH; Fan YM; Li T; Zhang LF; Mui C; Fan HW; Zhou BT; Liu ZY; Ng H; Liu XQ
    Chin Med J (Engl); 2013 Jun; 126(12):2333-6. PubMed ID: 23786949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome.
    Seto WK; Lai CL; Fung J; Wong DK; Yuen JC; Hung IF; Yuen MF
    J Hepatol; 2011 Sep; 55(3):522-528. PubMed ID: 21147187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels.
    Lv GC; Ma WJ; Ying LJ; Jin X; Zheng L; Yang YD
    World J Gastroenterol; 2010 Aug; 16(32):4095-9. PubMed ID: 20731026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients].
    Huang J; Chen XP; Chen XF; Chen WL; Chen R; Ma XJ; Luo XD
    Zhonghua Gan Zang Bing Za Zhi; 2011 Mar; 19(3):178-81. PubMed ID: 21586234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
    Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telbivudine for the management of chronic hepatitis B virus infection.
    Matthews SJ
    Clin Ther; 2007 Dec; 29(12):2635-53. PubMed ID: 18201580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telbivudine for the treatment of chronic hepatitis B infection.
    Hartwell D; Jones J; Harris P; Cooper K
    Health Technol Assess; 2009 Oct; 13 Suppl 3():23-30. PubMed ID: 19846025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical antiviral effects of telbivudine in patients with chronic hepatitis B].
    Xu Y; Wang JB; Ji SW; Zhang YG; Siqingtu NL; Zhao P; Guo HH; Li Y; Jiao J; Zhou CY
    Zhonghua Gan Zang Bing Za Zhi; 2010 Apr; 18(4):259-62. PubMed ID: 20460043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.